GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Debt-to-Asset

Avecho Biotechnology (ASX:AVE) Debt-to-Asset : 0.02 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Debt-to-Asset?

Avecho Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.08 Mil. Avecho Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.10 Mil. Avecho Biotechnology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$7.32 Mil. Avecho Biotechnology's debt to asset for the quarter that ended in Dec. 2023 was 0.02.


Avecho Biotechnology Debt-to-Asset Historical Data

The historical data trend for Avecho Biotechnology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Debt-to-Asset Chart

Avecho Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.05 0.02 0.07 0.02

Avecho Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.07 0.05 0.02

Competitive Comparison of Avecho Biotechnology's Debt-to-Asset

For the Biotechnology subindustry, Avecho Biotechnology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Debt-to-Asset falls into.



Avecho Biotechnology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Avecho Biotechnology's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Avecho Biotechnology's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (ASX:AVE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Avecho Biotechnology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology (ASX:AVE) Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines